NCT07070518 - Study of GV20-0251 in Participants With Solid Tumor Malignancies | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

July 11, 2025

Primary Completion Date

July 16, 2027

Study Completion Date

September 16, 2028

Conditions

Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)Squamous Head and Neck CarcinomapMMR/MSS Adenocarcinoma of the Colon or RectumNon-Small Cell Lung CancerMelanomaHCC - Hepatocellular CarcinomaSmall Cell Lung Cancer

Interventions

DRUG

GV20-0251

Part A: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks Part B: GV20-0251 preliminary RP2D administered by IV infusion once every 3 weeks

Trial Locations (1)

Unknown

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing